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Introduction
With more than 41 million annual deaths, non-com-
municable diseases (NCDs) and their associated risk 
factors pose important challenges for global health.1,2 In 
the Americas, almost 6 million of the 7 million deaths 
that occurred in 2017 were due to NCDs, 14% of the total 
global deaths due to NCDs.3 Although countries in 
some subregions of the Americas share many cultural, 
economic, and developmental similarities, differences in 
urbanisation, pace, and timing of the demographic, 
nutritional, and epidemiological transitions have led 
to high hetero geneity in the burden of NCDs across 
countries in the region. In 2017, the age-standardised 
mortality rate for NCDs in the region ranged from less 
than 350 deaths per 100 000 people in Peru, Colombia, 
and Canada to more than 890 deaths per 100 000 people 
in Haiti, more than that observed in any other country 
in the region in 1990.2
As part of the challenges posed by the increasing burden 
of NCDs in the region, the plan of action of the Pan 
American Health Organization strategy for the prevention 
and control of NCDs, 2021–25, was set with the aim to 
reduce avoidable mortality and morbidity associated with 
NCDs, and to minimise the exposure to risk factors, 
through a series of actions at the regional and national 
levels. This initiative aligned with the WHO NCD Global 
Monitoring Framework and Global Action Plan 2013–20.4,5
Describing the trends of cardiometabolic risk factors 
associated with NCDs is crucial for monitoring progress, 
planning prevention, and providing evidence to support 
policy efforts.5,6 Previous analyses have either focused on 
the trends and burden of single risk factors in the 
region,7–10 or on cross-sectional analyses without exploring 
changes over time.11 Given the relevance of these risk 
factors for health policy and decision-making, and 
focusing exclusively on the Americas, we aimed to 
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analyse national and subregional trends, from 1980 to 
2014, in mean body-mass index (BMI), obesity, mean 
systolic blood pressure, raised blood pressure, and 
diabetes in adults.
Methods
Study design and data sources
Data used in this analysis were obtained from population-
based surveys, pooled and analysed by the NCD Risk 
Factor Collaboration (NCD-RisC) and have been described 
in detail elsewhere (appendix p 2).7–9 Briefly, we accessed 
publicly available population-based multicountry and 
national measurement surveys (eg, Demographic and 
Health Surveys, Global School-based student Health 
Surveys, and surveys identified via the Inter-University 
Consortium for Political and Social Research and the 
European Health Interview and Health Examination 
Surveys Database) as well as the WHO STEPwise 
approach to Surveillance surveys. Anonymised individual 
record data from sources included in NCD-RisC were 
reanalysed by the Pooled Analysis and Writing Group or 
by data holders according to a common protocol.
We analysed national and regional trends in mean BMI, 
prevalence of obesity, mean systolic and diastolic blood 
pressure, prevalence of raised blood pressure (systolic 
blood pressure ≥140 mm Hg or diastolic blood pressure 
≥90 mm Hg), and prevalence of diabetes (fasting plasma 
glucose ≥7·0 mmol/L, history of diabetes, or diabetes treat-
ment) in adults aged 18 years and older, in the 37 countries 
of the Americas. For mean BMI and prevalence of obesity, 
results are reported for ages 20 years and older. Although 
the NCD-RisC has released estimates for BMI, prevalence 
of obesity, mean systolic and diastolic blood pressure, and 
prevalence of raised blood pressure up to 2016, estimates 
for diabetes are only available up to 2014. To maintain 
consistency in the analysis across the three risk factors, 
the study period was limited to 1980–2014. Additionally, 
although estimates for BMI prevalence were available for 
seven different categories (<18·5 kg/m², 18·5 to <20 kg/m², 
20 to <25 kg/m², 25 to <30 kg/m², 30 to <35 kg/m², 
35 to <40 kg/m², and ≥40 kg/m²), we report the prevalence 
of obesity (BMI ≥30 kg/m²) only, which is of key public 
health concern in the Americas.
Estimates were obtained using population-based data 
sources representative of national, subnational (ie, covering 
≥1 subnational region, or >3 communities) or community 
(≤3 communities) levels, with measured height or weight, 
systolic or diastolic blood pressure, or at least one of the 
following diabetes biomarkers: fasting plasma glucose 
(FPG), oral glucose tolerance (OGTT), or HbA1c. Conver-
sion of diabetes biomarkers to a common definition is 
described elsewhere.9
Statistical analysis
Analyses were done separately for men and women, 
using a Bayesian model to obtain estimates by age 
group, country, and year. The model used here has been 
described and validated previously (appendix p 2).7–9,12 
The model had a hierarchical structure, in which 
estimates for each country and year were informed by 
their own data, data from other years in the same 
country, and data in other countries in the same region.13 
The hierarchical structure shared information to a 
greater degree when data were non-existent or weakly 
informative (eg, a study with a small sample size is less 
informative than a study in the same country and year 
For more on the NCD Risk Factor 
Collaboration see www.ncdrisc.
org
See Online for appendix
Research in context
Evidence before this study
We searched MEDLINE (using PubMed) using the terms 
((hypertension[Title] OR “blood pressure”[Title]) OR 
(diabetes[Title] OR “type 2 diabetes”[Title]) OR (BMI[Title] OR 
“body mass index”[Title])) AND (“Americas”[Mesh]). We did 
not find national estimates for all risk factors reported in this 
study (ie, studies were largely done in limited regions or sites). 
The search yielded two reviews of diabetes and obesity 
prevalence in Latin American countries, published in 2002, 
indicating that an update of this evidence is warranted. Overall, 
the available evidence was limited to country-based research on 
the epidemiology of cardiometabolic risk factors. Comparable 
metrics between countries in the Americas region covering a 
large study period have not been published.
Added value of this study
This work provides the most comprehensive analysis of trends in 
cardiometabolic risk factors, namely body-mass index, 
blood pressure, and diabetes in the Americas. This research 
covers a substantially longer period (1980–2014) than that of 
any previous work and provides estimates for 37 countries and 
territories in the Americas. Our results suggest that the frequency 
of high body-mass index and diabetes has increased throughout 
the region and, conversely, the prevalence of raised blood 
pressure appears to have decreased over time. The findings 
suggest that countries with a high prevalence of a particular risk 
factor do not necessarily also have a high frequency of another 
risk factor. The results signal different patterns of convergence 
and divergence between risk factors within subregions.
Implications of all the available evidence
Despite the decline in the prevalence of raised blood pressure 
across the region, much work is still needed to curtail the 
increasing burden of high body-mass index and diabetes. 
Cardiometabolic risk factors are rising on the public health 
agenda of governments in the Americas, particularly among 
low-income and middle-income countries in the region. 
This momentum can benefit from the use of regional trends 
from this study, which will inform policy and action in the 
Americas.
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with a larger sample), and to a lesser extent for data-rich 
countries and subregions.
The model incorporated non-linear time trends and age 
patterns, allowing the age pattern to vary across countries. 
The model accounted for the possibility that the risk 
factors in subnational and community samples might 
systematically differ from nationally representative ones 
and have a larger variation than in national studies. These 
features were implemented by including data-driven 
fixed-effect and random-effect terms for subnational and 
community data. The fixed effects adjusted for systematic 
differences between subnational or community studies 
and national studies. The random effects allowed national 
data to have a larger influence on the estimates than those 
of subnational or community data with similar sample 
sizes. The model also accounted for rural–urban dif-
ferences in risk factors, using data-driven fixed effects for 
rural-only and urban-only studies. These rural and urban 
effects were weighted by the difference between study-
level and country-level urban isation in the year when the 
study was done. The statistical model included country-
level covariates that were specific to each of the risk 
factors: the proportion of the national population living 
in urban areas for BMI; average number of years of 
education, proportion of national population living in 
urban areas, a summary measure of the availability of 
different food types for human consumption for diabetes 
and blood pressure; and age-standardised adult mean 
BMI for diabetes.
We fitted this Bayesian model with the Markov chain 
Monte Carlo (MCMC) algorithm. We ran 55 000 iterations, 
monitoring convergence, and discarded 5000 to give 
50 000 iterations. We then thinned the chains, to give 
5000 iterations for each chain. The 20 chains were then 
combined, and further thinning was carried out to give 
the final 5000 samples from the posterior distribution of 
model parameters, which were then used to obtain the 
posterior distributions. The reported credible intervals 
(CIs) represent the 2·5th to 97·5th percentiles of the 
posterior distributions. Reported estimates were age-
standardised using the WHO standard population.14 
Results are presented at the subregional and country 
levels. Classification of countries into subregions (using 
posterior estimates) is described in the appendix (p 7) 
and classification of the countries is based on 
geographical, cultural, and epidemiological similarities 
among countries. To assess the correlation between risk 
factors, we used Spearman’s correlation rank test for risk 
factor prevalence. Probabilities of increases or decreases 
in risk factors were calculated using the proportion of 
MCMC draws in which increases or decreases were 
observed.
Figure 1: Number of data sources available for body-mass index, blood pressure, and diabetes by subregion and year
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Role of the funding source
The funder of the study had no role in study design, data 
collection, analysis, interpretation, or writing of the 
report. The corresponding authors had full access to the 
data in the study. The corresponding authors had final 
responsibility for the decision to submit for publication.
Results
We used 389 population-based surveys from the Americas, 
of which 236 had information on BMI (1 783 267 par-
ticipants), 223 had information on blood pressure 
(1 042 131 participants), and 108 had information on 
diabetes (284 555 participants). Among the 37 countries 
included, four (11%; Antigua and Barbuda, Bahamas, 
Bermuda, and Saint Vincent and the Grenadines) had no 
studies available (figure 1; appendix p 7).
From 1980 to 2014, the age-standardised mean BMI, 
and the age-standardised prevalence of obesity and 
diabetes increased in both sexes in all subregions in 
the Americas, whereas the age-standardised prevalence 
of raised blood pressure and the age-standardised mean 
systolic blood pressure declined in some subregions 
and did not change in others (figure 2; appendix 
pp 10, 11, 20, 21).
Obesity (and, similarly, mean BMI) increased every-
where in the region, with the fastest increase observed in 
the non-English-speaking Caribbean subregion, with the 
prevalence of obesity going from 3·9% (95% CI 2·2–6·3) 
in 1980, to 18·6% (14·3–23·3) in 2014, in men; and from 
12·2% (8·2·17–0) in 1980, to 30·5% (25·7–35·5) in 2014, 
in women (figure 2). The English-speaking Caribbean 
subregion ranked first for prevalence of diabetes: 
11·1% (6·4–17·3) in men and 13·6% (8·2–21·0) in 
women in 2014, with prevalence being 2·1 times larger 
(for men and women) in 2014 than in 1980 (figure 2). A 
decrease in raised blood pressure was observed in all 
subregions, regardless of the prevalence observed in 
1980, with the largest decline being in North America, 
from 27·6% (22·3–33·2) in men and 19·9% (15·8–24·4) 
in women in 1980, to 15·5% (11·1–20·9) in men and 
10·7% (7·7–14·5) in women in 2014 (figure 2; appendix 
pp 10–12).
Although mean systolic blood pressure has declined 
since the early 2000s, this trend appears to have 
Figure 2: Trends in age-standardised prevalence of obesity, raised blood pressure, and diabetes by subregion in men and women
The lines show the posterior mean estimates and the shaded areas show the 95% credible intervals.
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stopped or reverted, particularly in North America, central 
Latin America, Andean Latin America, and southern 
Latin America for men and in North America and 
central Latin America for women (appendix pp 20, 21). 
Conversely, mean BMI increased almost linearly until the 
early 2000s, when this pace seems to have slowed down 
in North America for both men and women and in 
Central America and Andean Latin America for women 
(appendix pp 20, 21).
The analysis of risk factor trends over time was 
complemented with an assessment of convergence or 
divergence of disease burden by subregions. The 
consistent risk factor trends that were observed in the 
region hid non-uniform subregional trends (figure 3). 
We found a regional convergence for both sexes in 
the prevalence of raised blood pressure over time 
(figure 3B), with countries in North America showing a 
conver gence towards much lower prevalence when 
compared with countries in the other subregions. A 
more complex pattern is observed in the prevalence 
of obesity (figure 3A) and diabetes (figure 3C), with a 
combination of subregional divergences, such as the 
variation in the prevalence of obesity in men or diabetes 
in women in all subregions.
The age-standardised prevalence of obesity, raised blood 
pressure, and diabetes for each country in 2014 are shown 
in figure 4 (appendix p 13), and corresponding estimates 
for 1980 are provided in the appendix (p 22). Country-
specific trends are available online.15 From 1980 to 2014, 
the age-standardised prevalence of obesity in men 
increased in every country, with a range of 2·1–2·5 times 
in Bermuda, Argentina, and Chile (probability of an 
increase 0·999 in Bermuda, >0·999 in Argentina, and 
>0·999, in Chile), to 8·3 times in Haiti (>0·999; 
figure 4A). In women, the age-standardised prevalence of 
obesity increased by 1·4 to 1·8 times in Bermuda (0·99), 
the Bahamas (>0·999), Uruguay (>0·999), and Venezuela 
(0·999) and 4·4 times in Haiti (>0·999; figure 4B). 
However, for men in 2014, the prevalence of obesity was 
greater than 20% in almost a third of all countries, with 
the USA ranking first, with 35·0% (95% CI 30·1–40·1); 
whereas for women, all countries had a prevalence of 
obesity above 20%, with 16 (43%) of 37 having a prevalence 
above 30% (figure 4).
Changes in the prevalence of raised blood pressure 
between 1980 and 2014 included a 50% reduction in 
Canada in men (probability >0·999) and a 60% reduction 
in Bermuda (0·999) in women (figure 4). Most countries 
showed declines in the prevalence of raised blood 
Figure 3: Boxplot showing the distribution of of country-level obesity, raised 
blood pressure, and diabetes prevalence
Coloured boxes show how country-level prevalences are distributed within 
subregions (as opposed to population-weighted subregional means), and large 
uncoloured boxes show the country-level distributions for the Americas as a whole. 
Solid lines show medians, the boxes show IQRs, and the whiskers show ranges.
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pressure, and the only two countries where increases 
were noted were in Saint Lucia (10%, probability 0·75 for 
men and 0·63 for women) and in Trinidad and Tobago 
(20%, 0·72 for men and 0·74 for women) for both sexes 
(figure 4). In 2014, the countries within the English-
speaking Caribbean and southern Latin America sub-
regions (Saint Lucia, Paraguay, Saint Kitts and Nevis, 
and Argentina) had the highest prevalence of raised 
blood pressure in men (range 27·9–29·8%), whereas for 
women highest prevalence was in the countries in both 
Caribbean subregions (figure 4).
Relative to that of 1980, all countries showed an 
increase in the prevalence of diabetes in both sexes. 
Diabetes in men increased from 1·2 times in Canada 
(probability 0·75) and Uruguay (0·69) to 4·1 times in 
Saint Lucia (0·99; figure 4A), and diabetes in women 
increased from 1·2-times in Canada (0·70) to 3·1 times 
in Saint Lucia (0.98; figure 4B). Similar to those of other 
risk factors, the highest estimates for prevalence of 
diabetes, up to 14·2% for men and 16·3% for women, 
were concentrated in the English-speaking Caribbean 
countries in both sexes.
In 2014, women showed a higher prevalence of obesity 
and diabetes than men did, but a lower prevalence of 
raised blood pressure (figure 5B), except for in the USA, 
Canada, Argentina, and Venezuela, where the prevalence 
of raised blood pressure and diabetes was higher in 
men than in women (figure 5B). The difference between 
men and women in 2014 was larger than that in 1980 
(figure 5A).
The comparison using Spearman’s correlation rank test 
of risk factor prevalence revealed a positive correlation 
between obesity and raised blood pressure (r=0·75 for 
men and r=0·67 for women), between obesity and diabetes 
(r=0·88 for men and r=0·80 for women), and between 
diabetes and raised blood pressure (r=0·74 for both sexes) 
in 1980, but not in 2014 (r=-0·25 for obesity and raised 
blood pressure, r=0·053 for obesity and diabetes, and 
r=0·51 for diabetes and raised blood pressure in men, and 
r=−0·22 for obesity and raised blood pressure, r=0·51 for 
obesity and diabetes, and r=0·49 for obesity and raised 
blood pressure in women; appendix p 23).
Discussion
This study provides a comprehensive assessment of 
obesity, raised blood pressure, and diabetes prevalence in 
the Americas between 1980 and 2014 and enhances our 
understanding of transitions in cardiometabolic risk 
factors in the region. Our estimates show that countries 
with the highest prevalence of a given cardiometabolic 
risk factor do not necessarily have the highest prevalence 
of another risk factor. The Americas has an obesity crisis 
accompanied by heterogeneous patterns of diabetes and 
raised blood pressure. These findings are important for 
the scoping and prioritisation of adequate NCD responses.
The increasing prevalence in obesity and diabetes 
observed in the region over time requires appropriate 
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measures to deal with these public health challenges. The 
reasons behind the disparity in the associations between 
obesity and diabetes or between obesity and raised blood 
pressure between subregions and in the same subregion 
at different times are multiple. Traditionally, the term 
diabesity has denoted the epidemiological parallelism 
between obesity and diabetes, which is understandable 
considering the shared pathophysiological mechanisms.16 
In terms of human capital, many countries in the Americas 
region are also transitioning from major burdens faced 
during childhood, particularly undernutrition.17,18 With this 
transition, the long-lasting effects of early undernutrition, 
a direct cause of nutritional stunting, could play a role in 
developing NCDs later in life.19
Our study expands the regional literature because we 
have included all countries with data covering 35 years, 
a period that has witnessed important socioeconomic 
changes in the Latin American and Caribbean regions. 
Our analysis showed that the prevalence of cardio-
metabolic risk factors, with the exception of raised blood 
pressure, has steadily increased, and we predict that 
the prevalence to continue to increase. Whereas pre-
vious studies have mostly focused on South America,20–23 
we included all countries from Central America and 
the Caribbean, as well as the USA and Canada. The 
evidence provided highlights how the heterogeneity in 
the prevalence of risk factors requires multisectoral and 
locally adapted responses to improve prevention and 
treatment.
Given the high level of heterogeneity observed in the 
region, our results would support a diversification of 
health interventions across subregions and countries. For 
example, the focus in North America should be on 
reducing the level of obesity, whereas countries in the 
other subregions are experiencing a real emergency, 
with interventions needed not only to reduce the prev-
alence of obesity but also to prevent diabetes and raised 
blood pressure. Countries with a low prevalence of 
cardiometabolic risk factors, such as Peru, Bolivia, and 
Ecuador, should focus on how to reverse the increasing 
trends, continue with good profiles, and implement new 
policies.24 For example, compared with other countries 
in Africa (South Africa) and Asia (China, India, and 
Pakistan), some countries in South America (Argentina, 
Chile, Peru, and Uruguay) have better rates of aware-
ness, treatment, and control of hypertension.25 However, 
inequalities within countries (and between countries) 
should be addressed to ensure that all population groups 
Figure 4: Heatmap of age-standardised prevalence of obesity, raised blood 
pressure, and diabetes by country in men and women in 2014, 
and proportional change from 1980
Countries are ranked by the prevalence of obesity. The ratio of prevalence for 
each risk factor are calculated for 2014 values relative to 1980 estimates. For the 
first three columns, red indicates the highest level in the prevalence of that 
specific risk factor and white the lowest; for the last three columns, purple 
indicates the highest ratio of prevalence and white the lowest.
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have these adequate patterns of awareness, treatment, 
and control of hypertension, such as in the USA, where 
Hispanic and black populations are characterised by 
different risk profiles when compared with the white 
population.26,27 Such heterogeneity is further exemplified 
by the INTERHEART study, in which the population 
attributable risk for acute myocardial infarction due to 
diabetes ranged from 7·4 in Colombia to 17·0 in Brazil.21
Our estimates focused on raised blood pressure instead 
of hypertension, which in epidemiological studies is a 
composite variable, including measured blood pressure, 
a diagnosis of hypertension, or whether currently re-
ceiving treatment for hypertension. Our results should 
be interpreted in this context. Nevertheless, the analysis 
of trends in raised blood pressure is key for the WHO 
NCD Global Monitoring Framework because one of 
the nine voluntary global targets is “a 25% reduction in 
the prevalence of raised blood pressure”.5 The declining 
trends in the prevalence of raised blood pressure could 
signal improvements in the awareness, treatment, and 
control of hypertension, which seems to be the case in 
Canada28 and the USA,27 although we are unaware of 
similar trends for other countries and subregions in the 
region.
Our findings also show that the prevalence of the three 
cardiometabolic risk factors was highest in the small 
countries in the Caribbean subregion. Although countries 
in this subregion vary in economic terms, the absolute 
population size might contribute to these poor health 
outcomes.29,30 With high prevalence and poor morbidity 
outcomes, this area is characterised by high levels of 
susceptibility, with limited ability to respond to the health 
needs of the population, including NCDs and chronic 
health issues, paired with limited health-care funding.
Tackling NCDs in the Americas will require high-risk 
approaches that are individual based, with population-based 
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Figure 5: Male vs female age-standardised prevalence of obesity, raised blood pressure, and diabetes in 1980 and 2014
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strategies.31,32 This study provides sufficient data-driven 
insights for decision making and serves as a baseline to 
monitor and assess the effect of initiatives to be 
implemented in the region.33 Our analysis offers a 
comprehensive picture and improved visualisation of the 
particular features of the region in terms of major 
cardiometabolic risks. However, limitations should also be 
acknowledged. First, because of data availability, we did 
not include other important cardio metabolic risk factors 
such as waist circumference, smoking, or lipid profile. 
We presented results for established cardiometabolic risk 
factors, accounting for their availability in rural and 
resource-limited settings. Second, we did not include data 
from children or adolescents, and future efforts should 
include these populations because cardiometabolic risk 
factors have also probably increased among them.34,35 
Third, good quality nationally representative data on 
cardiometabolic risk factors are still absent in some 
countries, especially in the Caribbean. We recognise that 
estimates from pooled analyses might differ slightly from 
national surveys, especially in data-poor countries, and the 
intention of this exercise is not to supersede local efforts 
but to maximise available resources and to support local 
endeavours to produce current comprehensive data.
This region-wide analysis is the result of a collective 
approach, maximising the existing data available with a 
common goal for the public good. To overcome some of 
the limitations, and to support cardiometabolic prevention 
interventions that are effective, national and inter national 
support should be provided to improve the surveillance 
system, with cross-sectional and cohort studies aimed at 
monitoring cardiometabolic risk factors, especially in 
data-poor countries, which would benefit the most from 
improved estimates.
We addressed some of the most important risk factors 
for NCDs, closing the gap in the lack of information on 
the prevalence of cardiometabolic risk factors in the 
Americas. Despite the high prevalence of cardiometabolic 
risk factors in the Americas, estimates show substantial 
variation exists between countries and subregions. 
Countries with the highest prevalence of one risk factor 
do not necessarily also stand out for another risk factor, 
and men’s profiles do not necessarily resemble those of 
women. Time trends show that, except for raised blood 
pressure, the prevalence of risk factors has steadily 
increased since 1980. Additionally, the within-region 
divergence in trends suggests that risk factors are not 
increasing or decreasing at the same pace in all countries. 
This study can signal opportunities for joint prevention 
efforts or interventions oriented to reduce common risk 
factors in the region, given the interconnectedness in 
cultural, social, demographic, ethnic, economic, and 
political aspects of the countries in the Americas.
Contributors
JJM, MDC, and ME initiated the study. All authors contributed to data 
collection, pooling analysis, and preparation of the results. JJM, RMCL, 
and MDC wrote the first draft with input from CF, IRH, PAL, RENM, 
BZ, JB, and DG. All other authors commented on the paper and 
contributed to the revision.
NCD Risk Factor Collaboration (NCD-RisC)—America Working Group
*Members contributed equally.
J Jaime Miranda (Universidad Peruana Cayetano Heredia, Peru); 
Rodrigo M Carrillo-Larco (Imperial College London, London, UK); 
Catterina Ferreccio (Pontificia Universidad Católica de Chile, Chile); 
Ian R Hambleton (The University of the West Indies, Barbados); 
Paulo A Lotufo (University of São Paulo, São Paulo, Brazil); 
Ramfis Nieto-Martínez (Miami Veterans Affairs Healthcare System, USA); 
Bin Zhou (Imperial College London, London, UK); James Bentham 
(University of Kent, UK); Honor Bixby (Imperial College London, London, 
UK); Kaveh Hajifathalian (Cleveland Clinic, USA); Yuan Lu 
(Yale University, USA); Cristina Taddei (Imperial College London, London, 
UK); Leandra Abarca-Gómez (Caja Costarricense de Seguro Social, 
Costa Rica)*; Benjamin Acosta-Cazares (Instituto Mexicano del Seguro 
Social, Mexico)*; Carlos A Aguilar-Salinas (Instituto Nacional de Ciencias 
Médicas y Nutrición, Mexico)*; Dolores S Andrade (Universidad 
de Cuenca, Ecuador)*; Maria Cecília F Assunção (Federal University 
of Pelotas, Brazil)*; Alberto Barceló (Pan American Health Organization, 
USA)*; Aluisio JD Barros (Federal University of Pelotas, Brazil)*; 
Mauro VG Barros (University of Pernambuco, Brazil)*; Iqbal Bata 
(Dalhousie University, Canada)*; Rosangela L Batista (Federal University 
of Maranhao, Brazil)*; Mikhail Benet (CAFAM University Foundation, 
Colombia)*; Antonio Bernabe-Ortiz (Universidad Peruana Cayetano 
Heredia, Peru)*; Heloisa Bettiol (University of São Paulo, Brazil)*; 
Jose G Boggia (Universidad de la República, Uruguay)*; 
Carlos P Boissonnet (Centro de Educación Médica e Investigaciones 
Clínicas, Argentina)*; Lizzy M Brewster (University of Amsterdam, 
Amsterdam, Netherlands)*; Christine Cameron (Canadian Fitness 
and Lifestyle Research Institute, Canada)*; Ana Paula C Cândido 
(Universidade Federal de Juiz de Fora, Brazil)*; Viviane C Cardoso 
(University of São Paulo, Brazil)*; Queenie Chan (Imperial College 
London, London, UK)*; Diego G Christofaro (Universidade Estadual 
Paulista, Brazil)*; Susana C Confortin (Universidade Federal de 
Santa Catarina, Brazil)*; Cora L Craig (Canadian Fitness and Lifestyle 
Research Institute, Canada)*; Eleonora d’Orsi (Universidade Federal de 
Santa Catarina, Brazil)*; Hélène Delisle (University of Montreal, Canada)*; 
Paula Duarte de Oliveira (Federal University of Pelotas, Brazil)*; 
Juvenal Soares Dias-da-Costa (Universidade do Vale do Rio dos Sinos, 
Brazil)*; Alejandro Diaz (National Council of Scientific and Technical 
Research, Argentina)*; Silvana P Donoso (Universidad de Cuenca, 
Ecuador)*; Paul Elliott (Imperial College London, London, UK)*; 
Jorge Escobedo-de la Peña (Instituto Mexicano del Seguro Social, Mexico)*; 
Trevor S Ferguson (The University of the West Indies, Jamaica)*; 
Romulo A Fernandes (Universidade Estadual Paulista, Brazil)*; 
Daniel Ferrante (Ministry of Health, Argentina)*; Eric Monterubio Flores 
(Instituto Nacional de Salud Pública, Mexico)*; Damian K Francis 
(The University of the West Indies, Jamaica)*; Maria do Carmo Franco 
(Federal University of São Paulo, Brazil)*; Flavio D Fuchs (Hospital de 
Clinicas de Porto Alegre, Brazil)*; Sandra C Fuchs (Universidade Federal 
do Rio Grande do Sul, Brazil)*; David Goltzman (McGill University, 
Canada)*; Helen Gonçalves (Federal University of Pelotas, Brazil)*; 
Juan P González-Rivas (The Andes Clinic of Cardio-Metabolic Studies, 
Venezuela)*; Mariano Bonet Gorbea (National Institute of Hygiene, 
Epidemiology and Microbiology, Cuba)*; Ronald D Gregor (Dalhousie 
University, Canada)*; Ramiro Guerrero (Universidad Icesi, Colombia)*; 
Andre L Guimaraes (State University of Montes Claros, Brazil)*; 
Martin C Gulliford (King’s College London, London, UK)*; 
Laura Gutierrez (Institute for Clinical Effectiveness and Health Policy, 
Argentina)*; Leticia Hernandez Cadena (National Institute of Public 
Health, Mexico)*; Victor M Herrera (Universidad Autónoma de 
Bucaramanga, Colombia)*; Wilma M Hopman (Kingston General 
Hospital, Canada)*; Andrea RVR Horimoto (Heart Institute, Brazil)*; 
Claudia M Hormiga (Fundación Oftalmológica de Santander, Colombia)*; 
Bernardo L Horta (Federal University of Pelotas, Brazil)*; Christina Howitt 
(The University of the West Indies, Barbados)*; Vilma E Irazola (Institute 
for Clinical Effectiveness and Health Policy, Argentina)*; 
Santa Magaly Jiménez-Acosta (National Institute of Hygiene, 
Epidemiology and Microbiology, Cuba)*; Michel Joffres (Simon Fraser 
Articles
e132 www.thelancet.com/lancetgh   Vol 8   January 2020
University, Canada)*; Patrick Kolsteren (Institute of Tropical Medicine, 
Belgium)*; Orlando Landrove (Ministerio de Salud Pública, Cuba)*; 
Yanping Li (Harvard TH Chan School of Public Health, USA)*; 
Christa L Lilly (West Virginia University, USA)*; M Fernanda Lima-Costa 
(Oswaldo Cruz Foundation Rene Rachou Research Institute, Brazil)*; 
Maria Wany Louzada Strufaldi (Federal University of São Paulo, Brazil)*; 
George LL Machado-Coelho (Universidade Federal de Ouro Preto, Brazil)*; 
Marcia Makdisse (Hospital Israelita Albert Einstein, Brazil)*; 
Paula Margozzini (Pontificia Universidad Católica de Chile, Chile)*; 
Larissa Pruner Marques (Universidade Federal de Santa Catarina, Brazil)*; 
Reynaldo Martorell (Emory University, USA)*; Alicia Matijasevich 
(University of São Paulo, Brazil)*; Anselmo J Mc Donald Posso (Gorgas 
Memorial Institute of Health Studies, Panama)*; Shelly R McFarlane 
(The University of the West Indies, Jamaica)*; Scott B McLean (Statistics 
Canada, Canada)*; Ana Maria B Menezes (Federal University of Pelotas, 
Brazil)*; Juan Francisco Miquel (Pontificia Universidad Católica de Chile, 
Chile)*; Salim Mohanna (Universidad Peruana Cayetano Heredia, Peru)*; 
Eric A Monterrubio (Instituto Nacional de Salud Pública, Mexico)*; 
Leila B Moreira (Universidade Federal do Rio Grande do Sul, Brazil)*; 
Alain Morejon (University Medical Science, Cuba)*; Jorge Motta 
(Gorgas Memorial Institute of Public Health, Panama)*; William A Neal 
(West Virginia University, USA)*; Flavio Nervi (Pontificia Universidad 
Católica de Chile, Chile)*; Oscar A Noboa (Universidad de la República, 
Uruguay)*; Angélica M Ochoa-Avilés (Universidad de Cuenca, Ecuador)*; 
Maria Teresa Anselmo Olinto (University of Vale do Rio dos Sinos, 
Brazil)*; Isabel O Oliveira (Federal University of Pelotas, Brazil)*; 
Lariane M Ono (Universidade Federal de Santa Catarina, Brazil)*; 
Pedro Ordunez (Pan American Health Organization, USA)*; Ana P Ortiz 
(University of Puerto Rico, Puerto Rico)*; Johanna A Otero (Fundación 
Oftalmológica de Santander, Colombia)*; Alberto Palloni (University of 
Wisconsin-Madison, USA)*; Sergio Viana Peixoto (Oswaldo Cruz 
Foundation Rene Rachou Research Institute, Brazil)*; Alexandre C Pereira 
(Heart Institute, Brazil)*; Cynthia M Pérez (University of Puerto Rico 
Medical Sciences Campus, Puerto Rico)*; Daniel A Rangel Reina (Gorgas 
Memorial Institute of Health Studies, Panama)*; Robespierre Ribeiro 
(Minas Gerais State Secretariat for Health, Brazil)*; Raphael M Ritti-Dias 
(Universidade Nove de Julho, Brazil)*; Juan A Rivera (Instituto Nacional 
de Salud Pública, Mexico)*; Cynthia Robitaille (Public Health Agency of 
Canada, Canada)*; Laura A Rodríguez-Villamizar (Universidad Industrial 
de Santander, Colombia)*; Rosalba Rojas-Martinez (Instituto Nacional 
de Salud Pública, Mexico)*; Joel GR Roy (Statistics Canada, Canada)*; 
Adolfo Rubinstein (Institute for Clinical Effectiveness and Health Policy, 
Argentina)*; Blanca Sandra Ruiz-Betancourt (Instituto Mexicano del 
Seguro Social, Mexico)*; Eduardo Salazar Martinez (National Institute of 
Public Health, Mexico)*; Jose Sánchez-Abanto (National Institute of 
Health, Peru)*; Ina S Santos (Federal University of Pelotas, Brazil)*; 
Renata Nunes dos Santos (University of Sao Paulo Clinics Hospital, 
Brazil)*; Marcia Scazufca (University of Sao Paulo Clinics Hospital, 
Brazil)*; Herman Schargrodsky (Hospital Italiano de Buenos Aires, 
Argentina)*; Antonio M Silva (Federal University of Maranhao, Brazil)*; 
Diego Augusto Santos Silva (Federal University of Santa Catarina, Brazil)*; 
Aryeh D Stein (Emory University, USA)*; Ramón Suárez-Medina 
(National Institute of Hygiene, Epidemiology and Microbiology, Cuba)*; 
Carolina B Tarqui-Mamani (National Institute of Health, Peru)*; Marshall 
K Tulloch-Reid (The University of the West Indies, Jamaica)*; Peter Ueda 
(Harvard TH Chan School of Public Health, USA)*; Eunice E Ugel 
(Universidad Centro-Occidental Lisandro Alvarado, Venezuela)*; 
Gonzalo Valdivia (Pontificia Universidad Católica de Chile, Chile)*; 
Patricia Varona (Epidemiology and Microbiology Institute, Cuba)*: 
Gustavo Velasquez-Melendez (Universidade Federal de Minas Gerais, 
Brazil)*; Roosmarijn Verstraeten (Institute of Tropical Medicine, 
Belgium)*; Cesar G Victora (Federal University of Pelotas, Brazil)*; 
Rildo S Wanderley Jr. (University of Pernambuco, Brazil)*; 
Ming-Dong Wang (Public Health Agency of Canada, Canada)*; 
Rainford J Wilks (The University of the West Indies, Jamaica)*; 
Roy A Wong-McClure (Caja Costarricense de Seguro Social, Costa Rica)*; 
Novie O Younger-Coleman (The University of the West Indies, Jamaica)*; 
Julio Zuñiga Cisneros (Gorgas Memorial Institute of Public Health, 
Panama)*; Goodarz Danaei (Harvard TH Chan School of Public Health, 
USA); Gretchen A Stevens (World Health Organization, Switzerland); 
Leanne M Riley (World Health Organization, Switzerland); Majid Ezzati 
(Imperial College London, London, UK); Mariachiara Di Cesare 
(Middlesex University, UK)
Declaration of interests
ME reports a charitable grant from the AstraZeneca Young Health 
Programme, and personal fees from Prudential, Scor, and Third Bridge, 
outside of the submitted work. All other authors declare no competing 
interests.
Acknowledgments
We thank WHO country and regional offices and the World Heart 
Federation for support in data identification and access. The study was 
supported by the Wellcome Trust. JJM acknowledges having received 
support from the Alliance for Health Policy and Systems Research 
(HQHSR1206660), the Bernard Lown Scholars in Cardiovascular Health 
Program at Harvard T H Chan School of Public Health (BLSCHP-1902), 
Bloomberg Philanthropies, FONDECYT via CIENCIACTIVA/
CONCYTEC, British Council, British Embassy, and the Newton-Paulet 
Fund (223-2018, 224-2018), DFID/MRC/Wellcome Global Health Trials 
(MR/M007405/1), Fogarty International Center (R21TW009982, 
D71TW010877), Grand Challenges Canada (0335-04), International 
Development Research Center Canada (IDRC 106887, 108167), 
Inter-American Institute for Global Change Research (IAI CRN3036), 
Medical Research Council (MR/P008984/1, MR/P024408/1, MR/
P02386X/1), National Cancer Institute (1P20CA217231), National Heart, 
Lung, and Blood Institute (HHSN268200900033C, 5U01HL114180, 
1UM1HL134590), National Institute of Mental Health (1U19MH098780), 
Swiss National Science Foundation (40P740-160366), Wellcome 
(074833/Z/04/Z, 093541/Z/10/Z, 107435/Z/15/Z, 103994/Z/14/Z, 
205177/Z/16/Z, 214185/Z/18/Z), and the World Diabetes Foundation 
(WDF15-1224). MDC is supported by an Academy of Medical Sciences 
Springboard Award, and JB by a Royal Society research grant.
References
1 World Health Organization. Noncommunicable Diseases Progress 
Monitor 2015. Geneva: WHO, 2015 http://www.who.int/nmh/
publications/ncd-progress-monitor-2015/en/ (accessed 
July 5, 2017).
2 GBD Compare. Institute for Health Metrics and Evaluation. 
https://vizhub.healthdata.org/gbd-compare/ (accessed 
Sept 25, 2019).
3 Global Burden of Disease (GBD). Institute for Health Metrics and 
Evaluation. https://vizhub.healthdata.org/gbd-compare/ (accessed 
Feb 5, 2019).
4 PAHO. Plan of action for the prevention and control of 
noncommunicable diseases in the Americas 2013–2019. Washington, 
DC: Pan American Health Organization, 2014. https://www.paho.org/
hq/dmdocuments/2014/NCD-en-lowres.pdf (accessed Sept 25, 2019).
5 WHO. Global action plan for the prevention and control of 
noncommunicable diseases 2013–2020. Geneva: World Health 
Organization, 2013.
6 Legetic B, Medici A, Hernández-Avila M, Alleyne G, Hennis A, 
editors. Economic Dimensions of Non-Communicable Disease in 
Latin America and the Caribbean. Disease Control Priorities. 3. ed. 
Companion Volume. Washington, DC: Pan American Health 
Organization, 2016.
7 NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends 
in blood pressure from 1975 to 2015: a pooled analysis of 
1479 population-based measurement studies with 19·1 million 
participants. Lancet 2017; 389: 37–55.
8 NCD Risk Factor Collaboration (NCD-RisC). Trends in adult 
body-mass index in 200 countries from 1975 to 2014: a pooled 
analysis of 1698 population-based measurement studies with 
19·2 million participants. Lancet 2016; 387: 1377–96.
9 NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends 
in diabetes since 1980: a pooled analysis of 751 population-based 
studies with 4·4 million participants. Lancet 2016; 387: 1513–30.
10 GBD 2015 Obesity Collaborators. Health effects of overweight and 
obesity in 195 countries over 25 years. N Engl J Med 2017; published 
online June 12. DOI:10.1056/NEJMoa1614362.
11 Miranda JJ, Herrera VM, Chirinos JA, et al. Major cardiovascular 
risk factors in Latin America: a comparison with the United States. 
The Latin American Consortium of Studies in Obesity (LASO). 
PLoS One 2013; 8: e54056.
Articles
www.thelancet.com/lancetgh   Vol 8   January 2020 e133
12 Finucane MM, Paciorek CJ, Danaei G, Ezzati M. Bayesian 
estimation of population-level trends in measures of health status. 
Stat Sci 2014; 29: 18–25.
13 Stevens GA, Singh GM, Lu Y, et al. National, regional, and global 
trends in adult overweight and obesity prevalences. 
Popul Health Metr 2012; 10: 22.
14 Ahmad OB, Boschi-Pinto C, Lopez AD, et al. Age standardization 
of rates: a new WHO standard. GPE Discussion Paper Series: 
No 31 EIP/GPE/EBD. Geneva: World Health Organization, 2001.
15  NCD-RisC. Data visualisations. NCD Risk Factor Collaboration 
http://ncdrisc.org/data-visualisations.html (accessed Nov 28, 2019).
16 Verma S, Hussain ME. Obesity and diabetes: an update. 
Diabetes Metab Syndr 2017; 11: 73–79.
17 Corvalán C, Garmendia ML, Jones-Smith J, et al. Nutrition status of 
children in Latin America. Obes Rev 2017; 18 (suppl 2): 7–18.
18 Smith LC, Haddad L. Reducing child undernutrition: past drivers 
and priorities for the post-MDG era. World Dev 2015; 68: 180–204.
19 Sawaya AL, Martins PA, Grillo LP, Florêncio TT. Long-term effects 
of early malnutrition on body weight regulation. Nutr Rev 2004; 
62: S127–33.
20 Rubinstein AL, Irazola VE, Calandrelli M, et al. Multiple 
cardiometabolic risk factors in the Southern Cone of Latin America: 
a population-based study in Argentina, Chile, and Uruguay. 
Int J Cardiol 2015; 183: 82–88.
21 Lanas F, Avezum A, Bautista LE, et al. Risk factors for acute 
myocardial infarction in Latin America: the INTERHEART 
Latin American study. Circulation 2007; 115: 1067–74.
22 Bautista LE, Casas JP, Herrera VM, et al. The Latin American 
Consortium of Studies in Obesity (LASO). Obes Rev 2009; 10: 364–70.
23 Schmidt MI, Duncan BB, Azevedo e Silva G, et al. Chronic 
non-communicable diseases in Brazil: burden and current 
challenges. Lancet 2011; 377: 1949–61.
24 Salicrup L, Ordunez P, Engelgau M. Hypertension control activities 
in Latin America and the Caribbean: opportunities for late-stage 
(T4) translation research. Rev Panam Salud Publica 2018; 42: e22.
25 Irazola VE, Gutierrez L, Bloomfield G, et al. Hypertension 
prevalence, awareness, treatment, and control in selected LMIC 
communities: results from the NHLBI/UHG network of centers of 
excellence for chronic diseases. Glob Heart 2016; 11: 47–59.
26 Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. 
Hypertension prevalence and control among adults: United States, 
2015–2016. NCHS data brief, no 289. Hyattsville, MD: National 
Center for Health Statistics, 2017.
27 Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, 
treatment, and control of hypertension, 1988-2008. JAMA 2010; 
303: 2043–50.
28 Campbell NRC, Chen G. Canadian efforts to prevent and control 
hypertension. Can J Cardiol 2010; 26 (suppl C): 14–17C.
29 Economic Commission for Latin America and the Caribbean 
(ECLAC). The Caribbean outlook, 2018. ECLAC. 2018. 
https://repositorio.cepal.org/11362/43581 (accessed Sept 26, 2019).
30 Hambleton IR, Howitt C, Jeyaseelan S, et al. Trends in longevity in 
the Americas: disparities in life expectancy in women and men, 
1965–2010. PLoS One 2015; 10: e0129778.
31 GBD 2016 Mortality Collaborators. Global, regional, and national 
under-5 mortality, adult mortality, age-specific mortality, and life 
expectancy, 1970–2016: a systematic analysis for the Global Burden 
of Disease Study 2016. Lancet 2017; 390: 1084–150.
32 Mendoza W, Miranda JJ. Global shifts in cardiovascular disease, 
the epidemiologic transition, and other contributing factors: toward 
a new practice of global health cardiology. Cardiol Clin 2017; 
35: 1–12.
33 Hospedales CJ, Barcelo A, Luciani S, Legetic B, Ordunez P, 
Blanco A. NCD prevention and control in Latin America and the 
Caribbean: a regional approach to policy and program development. 
Glob Heart 2012; 7: 73–81.
34 Rivera JÁ, de Cossío TG, Pedraza LS, Aburto TC, Sánchez TG, 
Martorell R. Childhood and adolescent overweight and obesity in 
Latin America: a systematic review. Lancet Diabetes Endocrinol 2014; 
2: 321–32.
35 NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in 
body-mass index, underweight, overweight, and obesity from 
1975 to 2016: a pooled analysis of 2416 population-based measurement 
studies in 128·9 million children, adolescents, and adults. Lancet 
2017; 390: 2627–42.
